VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced that the Company will be hosting its Annual General Meeting of Shareholders at 9 a.m. (Pacific Time) in Vancouver, BC.
An audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company is currently developing voclosporin, an investigational drug, for the treatment of LN. The Company is headquartered in Victoria, BC and focuses its development efforts globally. www.auriniapharma.com
Aurinia Pharmaceuticals Inc.
Vice President, Public Affairs
Source: Aurinia Pharmaceuticals Inc.
Released June 21, 2017